Last edition
News about "Phase 3 FOCUS-3 clinical trial "
Axsome Doses First Patient in Phase 3 Trial of Solriamfetol for Adolescent ADHD
Axsome Therapeutics has initiated patient dosing in the Phase 3 FOCUS-3 trial evaluating solriamfetol as a potential treatment for adolescents with Attention Deficit Hyperactivity Disorder.
Phase 3 FOCUS-3 Clinical Trial | 01/07/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members